Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation

@article{Cibrik2013RandomizedTO,
  title={Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation},
  author={D. Cibrik and H. Silva and A. Vathsala and E. Lackov{\'a} and C. Cornu-Artis and R. Walker and Zailong Wang and G. Zibari and F. Shihab and Yu Seun Kim},
  journal={Transplantation Journal},
  year={2013},
  volume={95},
  pages={933–942}
}
Background Strategies allowing calcineurin inhibitor minimization while maintaining efficacy may improve renal transplant outcomes. Methods A2309 was a 24-month, phase IIIb, open-label trial of 833 de novo renal transplant recipients randomized to everolimus, targeting trough concentrations of 3–8 or 6–12 ng/mL plus reduced-exposure cyclosporine A (CsA) or to mycophenolic acid (MPA) 1.44 g per day plus standard-exposure CsA. All patients received basiliximab±corticosteroids. The incidence of… Expand
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial
  • K. Budde, M. Zeier, +15 authors C. Sommerer
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2017
Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
  • S. Berger, C. Sommerer, +18 authors J. Pascual
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2019
Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus
  • F. Shihab, Y. Qazi, +4 authors D. Shaffer
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2017
Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant Recipients
  • H. Silva Jr., D. Cibrik, +7 authors Y. Kim
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2010
Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and Tacrolimus
  • T. Larson, P. Dean, +11 authors J. Velosa
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2006
Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids
  • M. Büchler, S. Caillard, +12 authors Y. Lebranchu
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine
  • A. Jardine
  • Medicine
  • Transplant international : official journal of the European Society for Organ Transplantation
  • 2005
Immunosuppressive Drugs in Kidney Transplantation
...
1
2
3
...